骨髓细胞免疫特征可独立预测骨髓增生异常综合征患者预后
该研究对176例原发性骨髓增生异常综合征(MDS)患者的骨髓样本行单样本基因集富集分析,构建基于Cox回归加权求和的MDS免疫风险(MIR)评分。高MIR评分与较高IPSS-R评分及ASXL1、RUNX1、TP53突变相关,且高评分患者无白血病生存(LFS)和总生存(OS)显著劣于低评分患者。MIR评分在IPSS-R各亚组中预后意义仍成立,并在两个独立队列中获验证;多因素分析显示较高MIR评分是LFS和OS的独立不良危险因素。
要点
- 高MIR评分与较高IPSS-R评分及ASXL1、RUNX1、TP53突变相关。
- 高MIR评分患者LFS和OS显著劣于低评分患者。
- MIR评分在IPSS-R亚组中预后意义成立,并在两个独立队列中获验证。
核心结论
- 骨髓细胞免疫特征构建的MIR评分可独立预测MDS患者的LFS和OS。
- MIR评分联合基因突变模型可作为IPSS-R的补充用于MDS预后判断。
研究设计与样本
- 研究纳入176例原发性MDS患者的骨髓样本。
- 采用单样本基因集富集分析对免疫特征进行评分。
- 基于Cox回归分析加权求和构建MDS免疫风险(MIR)评分系统。
- 预后意义在两个独立队列中进行验证。
主要发现
- 未成熟树突状细胞和CD56bright自然杀伤细胞特征增强与较好OS相关。
- 较高CD103+特征与生存缩短相关。
- 高MIR评分与较高IPSS-R评分及ASXL1、RUNX1、TP53突变相关。
- 高评分患者LFS和OS显著劣于低评分患者。
- 多因素分析显示较高MIR评分是LFS和OS的独立不良危险因素。
关键数值与推荐
- MIR评分基于Cox回归分析的加权求和构建。
- 高MIR评分与较高修订版国际预后评分系统(IPSS-R)评分相关。
- 高MIR评分与ASXL1、RUNX1、TP53突变相关。
- MIR评分的预后意义在IPSS-R各亚组中均成立。
临床怎么用
- MIR评分可用于MDS患者预后分层,辅助IPSS-R判断LFS和OS。
- MIR评分联合基因突变模型可补充IPSS-R用于MDS预后评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Increasing evidence supports the role of the immune microenvironment and associated signalling in the pathogenesis of myelodysplastic syndromes (MDS). Nevertheless, the clinical relevancy of immune signals in patients with MDS remains elusive. To address this, we used single-sample gene-set enrichment analysis to score immune signatures of bone marrow (BM) samples from 176 patients with primary MDS. Enhanced signatures of 'immature dendritic cells' and 'natural killer cells with cluster of differentiation (CD)56bright' were correlated with better overall survival (OS), whilst higher 'CD103+ signature' was associated with reduced survival. An MDS-Immune-Risk (MIR) scoring system was constructed based on the weighted sums derived from Cox regression analysis. High MIR scores were correlated with higher revised International Prognostic Scoring System (IPSS-R) scores and mutations in ASXL transcriptional regulator 1 (ASXL1), Runt-related transcription factor 1 (RUNX1), and tumour protein p53 (TP53). High-score patients had significantly inferior leukaemia-free survival (LFS) and OS than low-score patients. The prognostic significance of MIR scores for survival remained valid across IPSS-R subgroups and was validated in two independent cohorts. Multivariable analysis revealed that a higher MIR score was an independent adverse risk factor for LFS and OS. We further proposed a model with the combination of MIR score and gene mutations to be complementary to IPSS-R for the prognostication of LFS and OS of patients with MDS.
引用
- Wang YH, Lin CC, Yao CY, et al. Immune signatures of bone marrow cells can independently predict prognosis in patients with myelodysplastic syndrome. Br J Haematol. 2021. PMID: 34536013. doi:10.1111/bjh.17837
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。